Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00785044 · ClinicalTrials.gov registry record
Study Dosed With (123I-mIBG) for Identifying Subjects With Heart Failure Who Will Experience an Adverse Cardiac Event
A clinical trial, sponsored by GE Healthcare.
- Completed
- Registry status
- 471
- Enrollment target
NCT00785044: Completed study, sponsored by GE Healthcare.
NCT00785044 is a clinical trial that has completed, run by GE Healthcare. The registered enrollment target is 471 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00785044 has completed, sponsored by GE Healthcare.
- COMPLETED
- Registry status
- 471 participants
- Enrollment target
Study Summary
The study was designed to study the utility of meta-iodobenzylguanidine (123I-mIBG) imaging to identify those participants with heart failure who would experience an adverse cardiac event during 24 months of follow-up from the administration date of 123I-mIBG in previous studies MBG311 or MBG312.
Primary Outcome
The numerical value of 123 I-mIBG uptake (H/M ratio) at 3 hours 50 minutes post administration was calculated by dividing the counts/pixel in the total myocardium region of interest (ROI) by the counts/pixel in the 7x7 pixel mediastinal ROI. Receiver operator characteristic curves (ROC) constructed on the basis of sensitivity and specificity to identify ACEs across all H/M values were used to calculate the area under the ROC curve (AUC). The AUC was used to test for statistical significance of t
Interventions
- DRUG I-123 mIBG
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 471 participants |
| Start Date | 2008-05 |
| Est. Completion | 2010-02 |
What the finished NCT00785044 record still lists
NCT00785044 is an observational study that tracks outcomes without assigning an intervention. The registered 471 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 1 intervention - of which I-123 mIBG is the first listed.
NCT00785044 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00785044 about?
NCT00785044 is a clinical study titled "Study Dosed With (123I-mIBG) for Identifying Subjects With Heart Failure Who Will Experience an Adverse Cardiac Event". The study was designed to study the utility of meta-iodobenzylguanidine (123I-mIBG) imaging to identify those participants with heart failure who would experience an adverse cardiac event during 24 months of follow-up from the administration date of 123I-mIBG in previous studies MBG311 or MBG312.
What is the current status of trial NCT00785044?
This trial is currently completed. The enrollment target is 471 participants. The study started on 2008-05. Estimated completion is 2010-02.
What interventions are being tested in trial NCT00785044?
The interventions under investigation include: I-123 mIBG (DRUG).
Who is sponsoring clinical trial NCT00785044?
This trial is sponsored by GE Healthcare, which has 99 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03010150 · 471 participants
Blood Tests and Questionnaires in Studying Adherence to Preventative Swallowing Exercises in Participants With Metastatic Head and Neck Cancer
- NCT05201404 · 471 participants · Phase 3
Namodenoson in the Treatment of Advanced Hepatocellular Carcinoma in Patients With Child-Pugh Class B7 Cirrhosis
- NCT06375083 · 472 participants · Phase 2
Computerized Cognitive Behavioral Therapies for Suicide Prevention and Depression
- NCT06947187 · 472 participants · NA
Vaccine Confidence and Infodemic in Southeast Asia's Nusantara Sociocultural Sphere
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia